Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04016935 · ClinicalTrials.gov registry record
EndoPredict® Extended Endocrine Trial (EXET)
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 855
- Enrollment target
NCT04016935: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT04016935 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 855 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04016935 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 855 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of using EndoPredict® clinically to inform treatment decisions for extended endocrine therapy, and the subsequent impact on patient outcomes.
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 855 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2022-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04016935
The ClinicalTrials.gov registry entry for NCT04016935 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 855 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT04016935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04016935 about?
NCT04016935 is a clinical study titled "EndoPredict® Extended Endocrine Trial (EXET)". The purpose of this study is to evaluate the impact of using EndoPredict® clinically to inform treatment decisions for extended endocrine therapy, and the subsequent impact on patient outcomes.
What is the current status of trial NCT04016935?
This trial is currently terminated. The enrollment target is 855 participants. The study started on 2019-07-02. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04016935?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT04016935?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.